Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

Clinical trial NCT06771544 · RECRUITING

Trial details

NCT number: NCT06771544
Sponsor: University of California, Irvine
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Melanoma Melanoma Stage III Melanoma (Skin)Melanoma Stage IV

Start date: 2024-12-23
Primary completion: 2027-12-01
Enrollment: 14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.